The DOI matches its Crossref record; 342 of the 342 references it cites were found in a registry or an index.
Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
Abstract
Parkinson's disease (PD), one of the most frequent neurodegenerative disorders, is no longer considered a complex motor disorder characterized by extrapyramidal symptoms, but a progressive multisystem or—more correctly—multiorgan disease with variegated neurological and nonmotor deficiencies. It is morphologically featured not only by the degeneration of the dopaminergic nigrostriatal system, responsible for the core motor deficits, but by multifocal involvement of the central, peripheral and autonomic nervous system and other organs associated with widespread occurrence of Lewy bodies and dystrophic Lewy neurites. This results from deposition of abnormal α‐synuclein (αSyn), the major protein marker of PD, and other synucleinopathies. Recent research has improved both the clinical and neuropathological diagnostic criteria of PD; it has further provided insights into the development and staging of αSyn and Lewy pathologies and has been useful in understanding the pathogenesis of PD. However, many challenges remain, for example, the role of Lewy bodies and the neurobiology of axons in the course of neurodegeneration, the relation between αSyn, Lewy pathology, and clinical deficits, as well as the interaction between αSyn and other pathologic proteins. Although genetic and experimental models have contributed to exploring the causes, pathomechanisms, and treatment options of PD, there is still a lack of an optimal animal model, and the etiology of this devastating disease is far from being elucidated. © 2011 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Self-citationAGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,651
Self-citationThe Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M., & Morris, J. G. L. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,246
Cited by
Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
Toledo, J. B., Arnold, S. E., Raible, K., Brettschneider, J., Xie, S. X., Grossman, M., Monsell, S. E., Kukull, W. A., & Trojanowski, J. Q. (2013) · Brain · doi:10.1093/brain/awt188 · Cited by 849
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859
Parkinson disease: from pathology to molecular disease mechanisms
Dexter, D. T., & Jenner, P. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.01.018 · Cited by 707
Thenganatt, M. A., & Jankovic, J. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.6233 · Cited by 506
Mitochondrial dynamics in neurodegeneration
Itoh, K., Nakamura, K., Iijima, M., & Sesaki, H. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2012.10.006 · Cited by 464
Kiely, A. P., Asi, Y. T., Kara, E., Limousin, P., Ling, H., Lewis, P., Proukakis, C., Quinn, N., Lees, A. J., Hardy, J., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1096-7 · Cited by 451
Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion‐Like Disorder?
Olanow, C. W., & Brundin, P. (2013) · Movement Disorders · doi:10.1002/mds.25373 · Cited by 390
Non motor subtypes and Parkinson's disease
Sauerbier, A., Jenner, P., Todorova, A., & Chaudhuri, K. R. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.09.027 · Cited by 375
Evolution of prodromal Parkinson’s disease and dementia with Lewy bodies: a prospective study
Fereshtehnejad, S.-M., Yao, C., Pelletier, A., Montplaisir, J. Y., Gagnon, J.-F., & Postuma, R. B. (2019) · Brain · doi:10.1093/brain/awz111 · Cited by 374
Risk factors for non-motor symptoms in Parkinson's disease
Marinus, J., Zhu, K., Marras, C., Aarsland, D., & van Hilten, J. J. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30127-3 · Cited by 348
Nonmotor features of Parkinson's disease subtypes
Marras, C., & Chaudhuri, K. R. (2016) · Movement Disorders · doi:10.1002/mds.26510 · Cited by 325
Kovacs, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020189 · Cited by 321
Alpha‐Synuclein as a Biomarker for Parkinson's Disease
Atik, A., Stewart, T., & Zhang, J. (2016) · Brain Pathology · doi:10.1111/bpa.12370 · Cited by 311
Freeman, R., Abuzinadah, A. R., Gibbons, C., Jones, P., Miglis, M. G., & Sinn, D. I. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.05.079 · Cited by 280
Aging of cerebral white matter
Liu, H., Yang, Y., Xia, Y., Zhu, W., Leak, R. K., Wei, Z., Wang, J., & Hu, X. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.11.006 · Cited by 260
The neurotoxicity of iron, copper and manganese in Parkinson's and Wilson's diseases
Dusek, P., Roos, P. M., Litwin, T., Schneider, S. A., Flaten, T. P., & Aaseth, J. (2015) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2014.05.007 · Cited by 253
Uchihara, T., & Giasson, B. I. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1485-1 · Cited by 249
Parkinson’s disease as a result of aging
Rodriguez, M., Rodriguez‐Sabate, C., Morales, I., Sanchez, A., & Sabate, M. (2015) · Aging Cell · doi:10.1111/acel.12312 · Cited by 214
Dupont, A.-C., Largeau, B., Santiago Ribeiro, M., Guilloteau, D., Tronel, C., & Arlicot, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040785 · Cited by 182
“Given the fact that a chronological spread of LB inclusions occurred in α-synucleinopathies [57], and these α-synuclein can directly provoke microglial activation [58], we could expect to find, in a time-dependent fashion, a widespread TSPO signal in PET imaging.”
BackgroundWiemerslage, L., & Lee, D. (2016) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2016.01.008 · Cited by 146
Gastrointestinal Dysfunctions in Parkinson’s Disease: Symptoms and Treatments
Poirier, A.-A., Aubé, B., Côté, M., Morin, N., Di Paolo, T., & Soulet, D. (2016) · Parkinson s Disease · doi:10.1155/2016/6762528 · Cited by 130
Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease
Milanese, C., Cerri, S., Ulusoy, A., Gornati, S. V., Plat, A., Gabriels, S., Blandini, F., Di Monte, D. A., Hoeijmakers, J. H., & Mastroberardino, P. G. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0848-7 · Cited by 118
Kamagata, K., Zalesky, A., Hatano, T., Ueda, R., Di Biase, M. A., Okuzumi, A., Shimoji, K., Hori, M., Caeyenberghs, K., Pantelis, C., et al. (2017) · Human Brain Mapping · doi:10.1002/hbm.23628 · Cited by 106
Imaging of Synaptic Density in Neurodegenerative Disorders
Carson, R. E., Naganawa, M., Toyonaga, T., Koohsari, S., Yang, Y., Chen, M.-K., Matuskey, D., & Finnema, S. J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263201 · Cited by 104
Wu, X., Yang, Z., Zou, J., Gao, H., Shao, Z., Li, C., & Lei, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02179-x · Cited by 88
Machado, V., Zöller, T., Attaai, A., & Spittau, B. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020151 · Cited by 76
The pathology roadmap in Parkinson disease
Surmeier, D. J., & Sulzer, D. (2013) · Prion · doi:10.4161/pri.23582 · Cited by 74
Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?
Gundersen, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.580311 · Cited by 33
Khan, A. F., Adewale, Q., Lin, S.-J., Baumeister, T. R., Zeighami, Y., Carbonell, F., Palomero-Gallagher, N., & Iturria-Medina, Y. (2023) · Nature Communications · doi:10.1038/s41467-023-41677-w · Cited by 28
Metadata
- Authors
- Jellinger, K. A.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2011-11-11
- Volume
- 27
- Issue
- 1
- Pages
- 8-30
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1979444935
- Cited by
- 451
- References
- 342
- FWCI
- 19.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.